Q-omics provides the consensus-scored PHACTR4 profile across patient tissues and cancer cell-line models. PHACTR4 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, PHACTR4 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, PHACTR4 RNA expression shows 20,722 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight SCLC, THCA, and ACC as cancer lineages where PHACTR4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PHACTR4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PHACTR4 survival associations across molecular data types. PHACTR4 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PHACTR4 RNA expression–survival associations across cancer types. High PHACTR4 expression shows unfavorable associations in LGG and ACC, but favorable associations in SCLC, KIRC, HNSC and UCS. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for PHACTR4 RNA expression.
This table summarizes PHACTR4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PHACTR4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PHACTR4 shows lower tumor expression in THCA and KICH and higher tumor expression in LIHC, CHOL, BLCA and UCEC. The THCA box plot shows higher PHACTR4 RNA expression in normal versus tumor tissue (log2 FC = −0.696, t-test p < 0.001).
This table shows molecular features associated with PHACTR4 in patient tissues and cancer cell lines. In patient samples, PHACTR4 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, PHACTR4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
